Amgen Submits MAA to EMA for ABP 501
Amgen submitted a market authorization application to EMA for ABP 501, a biosimilar candidate to Humira.
On Dec. 4, 2015, Amgen announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for ABP 501, a biosimilar candidate to Humira (adalimumab). This is Amgen’s first biosimilar submission to the European Union (EU).
ABP 501 is a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of various inflammatory diseases. Phase III comparative efficacy and safety studies were conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. According to the company, the results showed clinical equivalence to adalimumab.
The company submitted a biologics license application (BLA) for ABP 501 to FDA in late November 2015. CEO Bob Bradway, said the company expects legal pushback from AbbVie, the original developer of Humira. AbbVie CEO, Richard Gonzalez, said they plan to aggressively defend patents for Humira, which he says will protect the product until 2022.
Source: Amgen
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
